# R-28 — Alloy M4 Face Cream Rx — Topical estriol

A prescription estrogen cream for menopausal skin, with a full ingredient list published and a placebo-controlled trial claimed — both firsts here. It also has a section headed 'Safety Information' that contains no safety information: no side effects, no contra-indications, no pregnancy note, and no mention of breast cancer on a page selling topical estrogen to women over fifty.

- **Canonical:** https://www.30plusskin.care/reviews/alloy-m4-face-cream-review
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## Verdict

- **Stance:** CAUTION — There is a real reason to hesitate. Read the finding before you buy.
- **Weighted score:** 59/100 across 75% of the scoring model
- **Score scope:** See assessed criteria
- **Category:** PRESCRIPTION COMPOUNDED / HORMONAL SKIN AGEING
- **Price:** $50 — PER MONTH · $150 PER 3-MONTH SUPPLY
- **Container size:** NOT PUBLISHED — '1 BOTTLE'
- **Prescription:** yes
- **Compounded:** yes
- **Assessment basis:** DESK REVIEW
- **Last updated:** 2026-07-28
- **Manufacturer page:** https://www.myalloy.com/solutions/m4

Two things here are better than anything else in this register. The full ingredient list is published, INCI-style and complete, on the page you buy from. And the efficacy claim rests on a stated placebo-controlled trial — 'statistically significant improvements... compared to placebo in just 12 weeks' — rather than the day-30 satisfaction surveys this category runs on. After twenty-seven reviews of uncontrolled self-report, a control arm is a genuinely different kind of claim.

The underlying science is also real, which we want to be clear about before criticising anything. Menopausal skin loses roughly 30% of its dermal collagen in the first five years, a figure the page cites accurately. Topical estriol for skin ageing has a small but genuine trial base going back to the 1990s. And the specific reassurance Alloy offers — that M4 can be used alongside HRT because it does not impact blood estrogen levels — is broadly supported: the controlled work on facial estriol measured serum FSH, prolactin and estradiol monthly and found no significant change.

But the page has a section headed 'Safety Information', and there is no safety information in it. What sits under that heading is a product description, an ingredient list, who it is for, what you get, and how to order. We searched the whole page for the things that heading promises. Side effects: zero mentions. Contra-indications: zero. Pregnancy: zero. Breast cancer: zero. This is a prescription estrogen sold specifically to perimenopausal and menopausal women, and the single most predictable question any of them will have — I have had, or am at risk of, a hormone-sensitive cancer, can I use this? — has no answer anywhere on it.

Two further omissions compound that. Estriol has no FDA-approved form in the United States, so M4 is necessarily a compounded preparation — and the page never says the word, though Alloy uses 'Compounded' in its own product names for three weight-loss drugs one menu away. And no concentration is given for the estriol, so a buyer cannot tell whether they are getting the 0.3% the trials used or something else entirely.

## Actives, as published

| Active | Concentration | Role | Benchmark | Assessment | Flagged |
| --- | --- | --- | --- | --- | --- |
| Estriol | Not published | Weak estrogen — binds dermal estrogen receptors, stimulates fibroblast collagen synthesis and hyaluronic acid production | 0.3% is the concentration used in the controlled facial trials | A legitimate and genuinely interesting choice with a real, if modest, evidence base for skin ageing. The mechanism is sound and the rationale — replacing what menopause removes — is the correct one. Two problems. The concentration is not published, so it cannot be matched to the trial range. And it is a hormone: even accepting that measurable serum change does not occur at facial doses, the population being sold to is precisely the one in which estrogen exposure is sometimes contraindicated, and the page addresses that nowhere. | yes |

## Scoring

| Criterion | Weight | Score | Note |
| --- | --- | --- | --- |
| EVIDENCE FOR THE ACTIVE | 30% | 70/100 | Topical estriol has a real trial base for skin elasticity, hydration and wrinkle depth, and the collagen-loss rationale is accurately cited. A placebo-controlled study is claimed, which is the strongest design asserted anywhere in this register. Held back because that study is named nowhere — no journal, no authors, no sample size, no link — because the percentages given are ambiguous about whether they describe subjects improved or magnitude of improvement, and because no concentration is published to compare against the 0.3% the literature uses. |
| FORMULATION INTEGRITY | 20% | 62/100 | A complete ingredient list, published on the page, fragrance-free, in a competent emollient base with dimethicone, glycerin, olive oil and vitamin E. That is more than most of this register manages. Marked down because the one number that matters — how much estriol — is absent, because no fill size is given for what is sold as a three-month supply, and because the compounded nature of the preparation is never acknowledged. |
| DISCLOSURE | 15% | 32/100 | Among the worst in the register, and uniquely so because the failure is signposted. A tab labelled 'Safety Information' contains none. Side effects, contra-indications, pregnancy and breast cancer each appear zero times on a page selling prescription estrogen to menopausal women. The compounded status and estriol's absence from the FDA-approved list are both unstated. Against that, real credit: the full ingredient list is published, the price and cadence are clear, and the collagen figure is accurate. |
| TOLERANCE IN USE | 15% | not scorable | Not assessed. The formulation reads as bland and well tolerated, and a hormone cream is unlikely to produce retinoid-style irritation — but the page offers no side-effect profile at all, so there is nothing even to check a panel against. |
| TEXTURE & WEAR | 10% | not scorable | Not assessed. Requires the product in hand across the twelve-week window. |
| COST PER APPLICATION | 10% | 58/100 | $150 for a stated three-month supply works out at $50 a month, with unlimited physician access, free delivery and HSA/FSA eligibility included — fair for a prescription product with a real consultation behind it. Held back because 'one bottle' is not a fill size, so cost per application cannot be computed, and because a 25% bundle discount is offered across three M4 products whose individual value is equally unquantifiable. |

_A criterion that cannot be assessed from published information is not guessed at. Its weight is removed from the denominator, and the coverage figure above says how much of the model survived._

## Strengths

- The full ingredient list is published on the page — complete, INCI-style, and fragrance-free.
- The efficacy claim rests on a stated placebo-controlled trial rather than a satisfaction survey.
- The collagen-loss rationale is accurate: roughly 30% of dermal collagen in the first five years of menopause, and about 2.1% a year after.
- Topical estriol is a genuinely interesting and evidenced choice for this specific population.
- The reassurance that it can be used alongside HRT is consistent with the controlled data on facial estriol.
- A twelve-week timeline, which matches the trial window rather than undercutting it.
- Prescription gating is real — a menopause-trained physician reviews medical history.
- $50 a month including unlimited doctor access, free delivery and HSA/FSA eligibility.
- Alloy states elsewhere that its physicians follow ACOG and Menopause Society guidance, and names a medical team.

## Weaknesses

- The section headed 'Safety Information' contains no safety information.
- Zero mentions of side effects, contra-indications, pregnancy or breast cancer on a prescription estrogen page.
- No guidance for women with a history of hormone-sensitive cancer, or on tamoxifen or an aromatase inhibitor.
- 'Topical estriol stays on the surface of your skin and doesn't enter your bloodstream' is mechanistically wrong, and contradicts the product's own claim to rebuild dermal collagen.
- Estriol has no FDA-approved form in the US, so M4 is compounded — and the page never says so, though Alloy labels three weight-loss drugs 'Compounded' one menu away.
- No concentration published for the estriol.
- No fill size; 'one bottle' is all that is offered for a three-month supply.
- The placebo-controlled study is cited to nobody — no journal, authors, sample size or link.
- '88% improvement in elasticity' does not say whether that is 88% of subjects or an 88% change.
- No sunscreen or SPF guidance anywhere on an anti-ageing page.

## Suits

- A perimenopausal or menopausal woman with no history of hormone-sensitive cancer, who wants a mechanism aimed at the actual cause of the change in her skin.
- Someone who has read the ingredient list, likes it, and will ask the prescriber for the estriol concentration.
- Someone who wants a prescription route with a menopause-trained physician included in the price.
- Someone already on HRT who wants a topical that will not complicate it — which, on the controlled evidence, it should not.
- Someone who will raise their own cancer and family history unprompted at the consultation.

## Avoid if

- You have a personal history of breast, endometrial or other hormone-sensitive cancer. Ask a specialist, not this page — it says nothing at all.
- You are taking tamoxifen or an aromatase inhibitor, where any additional estrogen exposure is a conversation to have first.
- You are pregnant or breastfeeding. The page offers no position; there should be one.
- You want to know how much of the active you are applying.
- You want a defined fill size so you can check that a bottle really is three months.

## The full assessment

### What it is

A prescription topical estrogen cream for facial skin, built around estriol, aimed specifically at perimenopausal and menopausal women. $150 for a stated three-month supply — $50 a month — including unlimited access to a menopause-trained physician, free delivery and HSA/FSA eligibility. A prescription is required and a doctor reviews medical history before it ships.

**RECORD**

| Field | Value |
| --- | --- |
| BRAND | ALLOY |
| PRODUCT | M4 FACE CREAM RX |
| ACTIVE | ESTRIOL — CONCENTRATION NOT PUBLISHED |
| CLASS | COMPOUNDED PRESCRIPTION HORMONE — NOT STATED AS SUCH |
| FDA STATUS | NO APPROVED ESTRIOL PRODUCT EXISTS IN THE US |
| FULL INGREDIENT LIST | PUBLISHED |
| FILL SIZE | NOT PUBLISHED — '1 BOTTLE' |
| STATED TIMELINE | 12 WEEKS |
| PRICE | $150 / 3 MONTHS · $50 PER MONTH |

### Start with what is genuinely good, because it is unusual

Two things on this page are better than anything we have assessed.

The reviewed Alloy page publishes an ingredient list, which makes the base more assessable than an ingredient-name menu alone. That is a finding about the cited offering, not proof that competitors withhold their bases. Agency now publishes formula-specific inactive ingredients on its current product pages; comparisons should use those updated records.

The second is the study design. Every headline figure in this register until now has been an uncontrolled satisfaction survey — 74%, 88%, 91%, all self-assessed at day 30 by paying customers with no control arm. Alloy claims something different: 'In an independent clinical study, statistically significant improvements seen in M4 Face Cream Rx compared to placebo in just 12 weeks.' A placebo arm and a significance test is a different order of claim, and it deserves saying so.

> **AND THE UNDERLYING SCIENCE HOLDS UP** — The rationale is the most biologically coherent in the register. Skin ageing after menopause is substantially estrogen-driven — roughly 30% of dermal collagen goes in the first five years, then about 2.1% a year, a figure the page cites accurately. Estrogen receptors are present on dermal fibroblasts, and topical estriol has a small controlled evidence base going back to the 1990s showing improvements in elasticity, firmness and wrinkle depth. Treating the cause rather than the symptom is exactly what we have spent twenty-seven reviews asking this category to do.

### The section called Safety Information

The page has three tabs: Details, Suggested Use, and Safety Information. We opened the third expecting the usual — a pregnancy line, a side-effect list, something about who should not use it.

What is under it is: what the product is, the full ingredient list, who it is for, what you receive, and how to obtain a prescription. That is a product description. There is no safety information in the Safety Information.

**FIG. 1 — SAFETY TERMS ON A PRESCRIPTION ESTROGEN PAGE** — Counted across the entire visible page, 28 July 2026. The active ingredient is named ten times. Every category of safety information a prescription hormone would ordinarily carry appears zero times — including on the tab headed 'Safety Information'.

| Item | Value (MENTIONS) | Note |
| --- | --- | --- |
| ESTRIOL — THE ACTIVE | 10 | Named throughout, and explained at length |
| SIDE EFFECTS | 0 | No adverse effect of any kind is described |
| CONTRA-INDICATIONS | 0 | No one is told not to use it |
| BREAST CANCER | 0 | On a topical estrogen sold to menopausal women |
| PREGNANCY OR BREASTFEEDING | 0 | No position offered |

_Scale maximum: 10MENTIONS._

> **THE QUESTION EVERY BUYER WILL HAVE** — Around one in eight women will be diagnosed with breast cancer, most commonly after fifty — which is precisely this product's market. Many of them are on tamoxifen or an aromatase inhibitor, where the whole point of treatment is suppressing estrogen. Whether a topical estriol cream is acceptable in that situation is a real clinical conversation with a defensible answer in either direction. This page does not have that conversation, mention that population, or use the words breast cancer at all. A prescriber may well raise it at the consultation. The page that takes the order does not.

### One sentence that is doing too much work

The reassurance the page offers instead is this: 'Topical estriol stays on the surface of your skin and doesn't enter your bloodstream, making it safe for everyday use.'

We want to be fair about the conclusion, because the conclusion is defensible. The controlled work on facial estriol measured serum FSH, prolactin and estradiol monthly across a six-month course and found no significant change. Alloy's related claim — that M4 can be used with or without HRT because it does not impact blood estrogen levels — is consistent with that evidence, and we are not disputing it.

The mechanism as stated is another matter. Estriol is a small lipophilic steroid. It does not stay on the surface of the skin; it cannot, because reaching the dermal fibroblasts is the entire basis of the product's collagen claim. A molecule that stayed on the surface would do nothing. The page therefore asserts, two paragraphs apart, that the active penetrates to the dermis to rebuild collagen and that it stays on the surface of the skin.

'No measurable change in serum hormone levels' and 'does not enter your bloodstream' are different statements, and the gap between them is exactly where a woman with a cancer history would want precision. The honest version is available, shorter, and still reassuring: at the doses used on facial skin, topical estriol has not been shown to raise circulating hormone levels.

### It is a compounded hormone, and the page never says so

There is no FDA-approved estriol product in the United States. Estriol is used widely in Europe and has never been approved here, which means any US estriol preparation is compounded by definition.

The page does not use the word compounded. It says 'prescription', 'bioidentical', 'plant based', and 'clinically proven'. It does not say that the FDA has approved no estriol product, or that compounded preparations are exempt from the premarket review that approved medicines undergo.

> **THE COMPANY USES THE WORD ONE MENU AWAY** — Alloy's own navigation lists 'Compounded Semaglutide', 'Compounded Tirzepatide' and 'Compounded Liraglutide' under weight care. So the word is in the house vocabulary and is applied plainly to three other products. It is not applied to the estriol cream, which is equally compounded and is a hormone.

There is a further tension worth noting without overstating it. Alloy's own promise section says its physicians follow guidance from leading medical organisations 'including ACOG and The Menopause Society'. ACOG has published a clinical consensus specifically on compounded bioidentical menopausal hormone therapy, and its position is cautionary — it prefers approved products where they exist and notes the absence of efficacy and safety review for compounded ones. Invoking ACOG while selling a compounded bioidentical hormone without saying it is compounded sits awkwardly.

### The study nobody can look up

Four figures anchor the page: 88% improvement in elasticity, 70% in hydration, 68% in overall skin health, 57% in texture, all against placebo at twelve weeks.

There is no journal, no authors, no year, no sample size and no link. 'An independent clinical study' is the entire citation. We credited Dermatica for putting real references with volume and page numbers on its ingredient pages; the contrast is that a company with a genuinely better study design has given readers no way to check it.

The numbers are also ambiguous in a way that matters. '88% improvement in elasticity' could mean 88% of subjects showed improvement, or that elasticity improved by 88%. Those are very different claims and the second would be extraordinary. A single clarifying word, or a link, would settle it.

### If you are considering it

- If you have any history of breast, endometrial or other hormone-sensitive cancer, or are on tamoxifen or an aromatase inhibitor, raise it at the consultation. Do not rely on this page, which says nothing.
- Ask for the estriol concentration and compare it against the 0.3% used in the published facial trials.
- Ask what the bottle actually contains in millilitres or grams, so you can check that it is a three-month supply.
- Ask the prescriber directly whether the preparation is compounded and where. The answer is yes, and the page will not tell you.
- Ask for the study. A placebo-controlled trial is worth reading and worth insisting on a citation for.
- If you are already on HRT, the evidence supports using this alongside it — but tell the prescriber anyway.
- Wear daily sunscreen. This is an anti-ageing product and the page never mentions it.
- Give it twelve weeks, which is the timeline the trial and the page agree on.

### Where we stand

At 59 this is a frustrating review to write, because the product may well be the most intelligent thing in the register. Menopausal skin ageing is substantially an estrogen-deficiency problem, almost nothing on the market treats it as one, and Alloy has built a prescription product that does — published its full ingredient list, run it against placebo, priced it fairly, and put a menopause-trained physician in front of it.

The caution is not about the estriol. It is that a prescription hormone is being sold to the exact population in which estrogen exposure sometimes must not happen, with a section headed Safety Information that contains none, no contra-indication of any kind, no mention of breast cancer, and a reassurance about absorption phrased more absolutely than the evidence or the product's own mechanism supports.

None of the fixes are hard. Put actual safety information under the heading that promises it. Name the one population that must ask first. Publish the estriol concentration and the fill size. Say the word compounded, as the company already does three products away. Cite the study. Do those and this becomes one of the best-argued products we have assessed — the science is already there, and it is the paperwork that is failing it.

## Where to buy

| Retailer | Price | Link | Note | Commission-bearing |
| --- | --- | --- | --- | --- |
| Alloy | $150 / 3 mo | https://www.myalloy.com/solutions/m4?utm_source=30plusskin&utm_medium=affiliate&utm_campaign=review&utm_content=alloy-m4-face-cream-review&utm_term=markdown | Prescription required; menopause-trained physician reviews your history. Unlimited doctor access included. | yes — affiliate link |

If you have any history of breast cancer or are on an aromatase inhibitor or tamoxifen, raise it before you order. This page will not raise it for you.

**Featured alternative:** [CoreAge Rx Time Out](https://www.coreagerx.com/product/time-out/?utm_source=30plusskin&utm_medium=affiliate&utm_campaign=review&utm_content=alloy-m4-face-cream-review&utm_term=markdown) — Estriol face cream with vitamin C and hyaluronic acid. From $48 / month advertised.

## Sources

- [Alloy — M4 Face Cream Rx product page](https://www.myalloy.com/solutions/m4) — The $150 three-month price, the full published ingredient list, the placebo-controlled claim and its four percentages, the collagen-loss figures, the 'stays on the surface... doesn't enter your bloodstream' claim, the 'used with or without HRT' claim, and the Safety Information section containing no safety information. Read 28 July 2026.
- [Schmidt et al. — Treatment of skin ageing with topical estrogens (Int J Dermatol, 1996)](https://pubmed.ncbi.nlm.nih.gov/8915735/) — 0.3% estriol versus 0.01% estradiol in 59 women over six months, with monthly serum FSH, prolactin and estradiol measurement showing no significant change — the trial base behind both the efficacy and the no-systemic-effect claim.
- [When applied to facial skin, does estrogen ointment have systemic effects? (PubMed)](https://pubmed.ncbi.nlm.nih.gov/8215610/) — The direct examination of systemic effects from facial estrogen application, underlying the assessment that Alloy's conclusion is defensible while its stated mechanism is not.
- [Topical estrogen therapy for aging skin: current evidence and clinical considerations (JAAD Reviews, 2025)](https://www.jaadreviews.org/article/S2950-1989(25)00103-5/fulltext) — Contemporary review of the topical estrogen evidence base for skin ageing.
- [ACOG — Compounded Bioidentical Menopausal Hormone Therapy (Clinical Consensus, 2023)](https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy) — The cautionary position on compounded bioidentical hormones from one of the two bodies Alloy states its physicians follow.
- [NASEM — The Clinical Utility of Compounded Bioidentical Hormone Therapy](https://www.ncbi.nlm.nih.gov/books/NBK562866/) — Confirms that no FDA-approved estriol product exists in the United States, so any US estriol preparation is compounded.

## Related records

- [L-07 Where the warning lives](/ledger/where-the-warning-lives)
- [L-05 Compounded is not approved](/ledger/compounded-is-not-approved)
- [R-29 Alloy M4 Body Treatment Rx](/reviews/alloy-m4-body-treatment-review) — CAUTION
- [R-30 Alloy M4 Eye Cream Rx](/reviews/alloy-m4-eye-cream-review) — CAUTION

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._